Abstract
Imetelstat is a first-in-class, direct, and competitive inhibitor of telomerase enzymatic activity that selectively induces apoptosis of malignant clones and allows for recovery of erythropoiesis. Imetelstat was approved by the United States Food and Drug Administration in June 2024 and the European Medicines Agency in March 2025 for the treatment of certain patients with lower-risk (low to intermediate-1) myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia who have failed or lost response to or are ineligible for erythropoiesis-stimulating agents. Imetelstat is infused at 7.1 mg/kg (active dose, equivalent to 7.5 mg/kg sodium salt) intravenously over 2 hours once every 4 weeks. In the pivotal IMerge trial in LR-MDS, significantly more patients treated with imetelstat vs. placebo, respectively, achieved ≥ 8-week RBC-transfusion independence (TI; 40% [95% confidence interval [CI] = 30.9–49.3] vs. 15% [95% CI = 7.1–26.6]) and ≥ 24-week RBC-TI (28% [95% CI = 20.1–37.0] vs. 3% [95% CI = 0.4–11.5]). The safety profile of imetelstat was characterized primarily by cytopenias, including neutropenia (incidence of 74% any grade and 68% grade 3–4 events) and thrombocytopenia (75% and 62%, respectively). Grade 3 to 4 hematologic events occurred early in the treatment and had a median duration of 1.9 weeks for neutropenia and 1.4 weeks for thrombocytopenia; cases resolved to grade ≤ 2 within 2 weeks in 81% and 86% of cases, respectively, with limited severe complications. This review highlights key topics related to the use of imetelstat in patients with LR-MDS, including its mechanism of action, clinical efficacy and safety data, dosing and administration, management of adverse events, and notable clinical practice implications.
References
Bodnar, A. G., Kim, N. W., Effros, R. B., & Chiu, C. P. (1996). Mechanism of telomerase induction during T cell activation. Experimental Cell Research, 228(1), 58–64. https://doi.org/10.1006/excr.1996.0299
Carraway, H. E., & Saygin, C. (2020). Therapy for lower-risk MDS. Hematology: the American Society of Hematology Education Program, 2020(1), 426–433. https://doi.org/10.1182/hematology.2020000127
Celgene Corporation, a Bristol-Myers Squibb Company. (2023). Revlimid (lenalidomide) [package insert]. https://packageinserts.bms.com/pi/pi_revlimid.pdf
Celgene Corporation, a Bristol-Myers Squibb Company. (2024). Reblozyl (luspatercept-aamt) [package insert]. https://packageinserts.bms.com/pi/pi_reblozyl.pdf
Della Porta, M. G., Garcia-Manero, G., Santini, V., Zeidan, A. M., Komrokji, R. S., Shortt, J., Valcárcel, D., Jonasova, A., Dimicoli-Salazar, S., Tiong, I. S., Lin, C. C., Li, J., Zhang, J., Pilot, R., Kreitz, S., Pozharskaya, V., Keeperman, K. L., Rose, S., Prebet, T.,...Platzbecker, U. (2024). Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): Primary analysis of a phase 3, open-label, randomised, controlled trial. The Lancet Haematology, 11(9), e646–e658. https://doi.org/10.1016/S2352-3026(24)00203-5
Fan, H.-C., Chang, F.-W., Tsai, J.-D., Lin, K.-M., Chen, C.-M., Lin, S.-Z., Liu, C.-A., & Harn, H.-J. (2021). Telomeres and cancer. Life, 11(12), 1405. https://doi.org/10.3390/life11121405
Fenaux, P., Haase, D., Santini, V., Sanz, G. F., Platzbecker, U., & Mey, U.; on behalf of the ESMO Guidelines Committee. (2021). Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 32(2), 142–156. https://doi.org/10.1016/j.annonc.2020.11.002
Geron Corporation. (2025). Rytelo (imetelstat) [summary of product characteristics]. https://www.ema.europa.eu/en/documents/product-information/rytelo-epar-product-information_en.pdf
Geron Corporation. (2024). Rytelo (imetelstat) [package insert]. https://pi.geron.com/products/US/pi/rytelo_pi.pdf
Harley, C. B. (2008). Telomerase and cancer therapeutics. Nature Reviews Cancer, 8(3), 167–179. https://doi.org/10.1038/nrc2275
Haumschild, R., Kennerly-Shah, J., Barbarotta, L., & Zeidan, A. M. (2024). Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review. Journal of Oncology Pharmacy Practice, 30(4), 721–736. https://doi.org/10.1177/10781552241238979
Jafri, M. A., Ansari, S. A., Alqahtani, M. H., & Shay, J. W. (2016). Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Medicine, 8(1), 69. https://doi.org/10.1186/s13073-016-0324-x
Kerbauy, D. B., & Deeg, H. J. (2007). Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Experimental Hematology, 35(11), 1739–1746. https://doi.org/10.1016/j.exphem.2007.09.007
Lennox, A. L., Huang, F., Behrs, M. K., González-Sales, M., Bhise, N., Wan, Y., Sun, L., Berry, T., Feller, F., & Morcos, P. N. (2024). Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational science. Clinical and Translational Science, 17(11), e70076. https://doi.org/10.1111/cts.70076
Lennox, A. L., Sun, L., Huang, F., Behrs, M. K., Kleiman, R., Xue, H., Bhise, N., Wan, Y., Berry, T., Feller, F., & Morcos, P. N. (2025). Low proarrhythmic risk of imetelstat, a novel oligonucleotide telomerase inhibitor: A translational analysis. Clinical and Translational Science, 18(2), e70169. https://doi.org/10.1111/cts.70169
Li, H., Hu, F., Gale, R. P., Sekeres, M. A., & Liang, Y. (2022). Myelodysplastic syndromes. Nature Reviews Disease Primers, 8(1), 74. https://doi.org/10.1038/s41572-022-00402-5
Lichtsteiner, S. P., Lebkowski, J. S., & Vasserot, A. P. (1999). Telomerase. A target for anticancer therapy. Annals of the New York Academy of Sciences, 886, 1–11. https://doi.org/10.1111/j.1749-6632.1999.tb09395.x
Nakamura, T. M., Morin, G. B., Chapman, K. B., Weinrich, S. L., Andrews, W. H., Lingner, J., Harley, C. B., & Cech, T. R. (1997). Telomerase catalytic subunit homologs from fission yeast and human. Science, 277(5328), 955–959. https://doi.org/10.1126/science.277.5328.955
National Cancer Institute. (2023). SEER Explorer: Myelodysplastic syndromes (MDS) SEER 5-year age-adjusted incidence rates, 2017–2021. https://seer.cancer.gov/statistics-network/explorer/
Platzbecker, U., Santini, V., Fenaux, P., Sekeres, M. A., Savona, M. R., Madanat, Y. F., Díez-Campelo, M., Valcarcel, D., Illmer, T., Jonášová, A., Bělohlávková, P., Sherman, L. J., Berry, T., Dougherty, S., Shah, S., Xia, Q., Sun, L., Wan, Y., Huang, F.,...Zeidan, A. M. (2024). Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): A multinational, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 403(10423), 249–260. https://doi.org/10.1016/S0140-6736(23)01724-5
Schanz, J., Tüchler, H., Solé, F., Mallo, M., Luño, E., Cervera, J., Granada, I., Hildebrandt, B., Slovak, M. L., Ohyashiki, K., Steidl, C., Fonatsch, C., Pfeilstöcker, M., Nösslinger, T., Valent, P., Giagounidis, A., Aul, C., Lübbert, M., Stauder, R.,...Haase, D. (2012). New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. Journal of Clinical Oncology, 30(8), 820–829. https://doi.org/10.1200/JCO.2011.35.6394
Sekeres, M. A., & Taylor, J. (2022). Diagnosis and treatment of myelodysplastic syndromes: A review. JAMA, 328(9), 872–880. https://doi.org/10.1001/jama.2022.14578
Steensma, D. P. (2018). Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer Journal, 8(5), 47. https://doi.org/10.1038/s41408-018-0085-4
Steensma, D. P., Fenaux, P., Van Eygen, K., Raza, A., Santini, V., Germing, U., Font, P., Diez-Campelo, M., Thepot, S., Vellenga, E., Patnaik, M. M., Jang, J. H., Varsos, H., Bussolari, J., Rose, E., Sherman, L., Sun, L., Wan, Y., Dougherty, S.,...Platzbecker, U. (2021). Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study. Journal of Clinical Oncology, 39(1), 48–56. https://doi.org/10.1200/JCO.20.01895
Tavares, R. E., Jesus, M. C. P., Cordeiro, S. M., Machado, D. R., Braga, V. A., & Merighi, M. A. B. (2017). Knowledge produced on the health of low-income older women: An integrative review. Revista Brasileira de Enfermagem, 70(4), 875–884. https://doi.org/10.1590/0034-7167-2017-0024
Wright, W. E., Piatyszek, M. A., Rainey, W. E., Byrd, W., & Shay, J. W. (1996). Telomerase activity in human germline and embryonic tissues and cells. Developmental Genetics, 18(2), 173–179. https://doi.org/10.1002/(sici)1520-6408(1996)18:2<173::aid-dvg10>3.0.co;2-3
Zeidan, A. M., Shallis, R. M., Wang, R., Davidoff, A., & Ma, X. (2019). Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Reviews, 34, 1–15. https://doi.org/10.1016/j.blre.2018.09.001
